Nostrum Labs, CEO to pay up to $50M in DOJ false claims case
By 
Kyle Brasseur2023-10-31T18:18:00
Pharmaceuticals firm Nostrum Laboratories and its founder and chief executive officer could pay up to $50 million as part of a settlement with the Department of Justice (DOJ) addressing alleged violations of the False Claims Act by underpaying Medicaid rebates.
Nostrum and CEO Nirmal Mulye agreed to pay at least $3.8 million, with the remainder of the settlement total to be determined based on their respective financial conditions, the DOJ announced in a press release Monday. Portions of the remaining money would be split among Medicaid-participating states as part of separate settlements, according to the agency’s settlement agreement.
The total would not exceed the $50 million figure.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefTeva Pharma to pay $450M to settle kickback, price-fixing allegations
Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of Justice (DOJ), including one alleging that co-pays it made on behalf of Medicare patients constituted illegal kickbacks, and a second action for alleged generic drug price fixing.
-
News BriefSilver Lake Hospital to pay $19M over Medicare false claims
New Jersey-based Silver Lake Hospital agreed to pay more than $18.6 million as part of a settlement with the Department of Justice addressing allegations of false claims submitted to Medicare for inpatient cost outlier payments.
-
News BriefCardiac Imaging, CEO to pay $85M in DOJ false claims case
Cardiac Imaging and its chief executive agreed to pay a total of more than $85 million to settle charges levied by the Department of Justice addressing alleged violations of the False Claims Act regarding unlawful kickbacks.
More from Regulatory Enforcement
-
ArticleSFO head to step down as speculation grows over future of agency
Nick Ephgrave, director of the U.K.’s main anti-corruption enforcement agency, the Serious Fraud Office, will retire at the end of March—about halfway through his appointed five-year term. Experts say he leaves the agency in a lot better position than he joined it in September 2023.
-
News BriefFTC puts GM’s puts connected vehicle data practices under compliance spotlight
The U.S. Federal Trade Commission finalized its order against General Motors and its OnStar subsidiary over the improper usage of geolocation and driving behavior data of drivers.
-
ArticleKaiser plans pay $556M to settle Medicare upcoding allegations
Kaiser Health affiliates have agreed to pay more than $556 million to settle allegations originally made by whistleblowers that they ignored compliance department warnings and unlawfully reworked diagnoses for Medicare patients in order to receive higher payments from the federal government.